Aarti Pharmalabs Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/n1zts56qum43ywhplhsq1csi.pdf

Key Takeaways


CDMO: The Growth Story

Gogri: "The 10 to 12 projects that we have out of the 60 projects, the 20% projects, will drive INR700 crores to INR800 crores of the revenue for out of the INR1,000 potential that we have overall."

Xanthine: Pricing Strength, Logistics Drag

Gogri: "We had little bit of lower Xanthine sales due to the shipments being held up due to shipment issues, but more sales on allied products. Otherwise, we would have ideally had higher sales in this quarter, but it was restricted due to these dispatch constraints."

API & Intermediates: Recovery Underway


Margins: Squeezed Now, Recovery Promised

Gogri: "Overall EBITDA percentage number can improve in the third and fourth quarter."

Capex, Balance Sheet & New Capabilities

Gogri: "I think next year will be the year where we will do a start, we will pitch to the customers and see how it goes and then I will be able to give you a firm commentary that how we are progressing on this."

Guidance & Commitments

CommitmentSpecificsTimeline
CDMO revenue growth40–50% growth over last yearFY27 and FY28
CDMO long-term revenue₹1,000 crores (or ₹10 crore, whichever comes first)Timing dependent on customer approvals
Xanthine volume growth15–20% jump over last year's ~6,000 volumeFY27
Xanthine capacity utilizationReach ~8,800 (90% of 9,600 nameplate)Over next two years
Xanthine dispatch constraintsResolved, sales numbers to increaseQ3 FY27
Atali Phase 1B capitalizationFull capitalizationQ3 FY27
Atali asset utilizationCompletely utilizedH2 FY27
Peptide lab operationalLabs with all equipment readyEnd of FY27
Total FY27 capex₹350–400 croresFY27
H2 capitalization ceilingNot to exceed ₹300 croresH2 FY27
API + intermediate quarterly base₹180–200 crores per quarterH2 FY27
API + intermediate long-term growth10–15% every yearOngoing
Xanthine absolute marginSustain existing absolute marginAt least through next financial year

Key Metrics

MetricQ2 FY27
Standalone revenue₹613 cr, +47% YoY (highest ever quarterly revenue)
Standalone EBITDA₹136 cr, +84% YoY
Standalone PAT₹66 cr, 2.75x YoY
Standalone EBITDA margin22.2%, vs 17.7% in Q2 FY26
Xanthine derivatives and allied products share50% of turnover
API and intermediate business share30% of turnover
CDMO/CMO share13% of revenue
Export sales share59% of total sales
CDMO active projects59 total, 39 in commercial stages, 20 under development
CDMO active customers23
CDMO revenue growth target40% to 50% over FY26
Xanthine volume growth guidance~15% over FY26 (FY26 volume close to 6,000)
Xanthine average realization increase10% to 15% over FY26
Xanthine capacity utilizationNear 7,000, nameplate capacity 9,600; next year anticipate 7,500 to 8,000
Working capital cycle165 to 167 days
Cash conversion cycle150 to 160 days, baseline for the business
Total capex targeted for FY27₹350 cr to ₹400 cr
API portfolio61 APIs